Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - QUESTCOR PHARMACEUTICALS INC | a56445exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2010
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
California | 001-14758 | 33-0476164 | ||
(State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
of Incorporation) | Identification No.) |
3260 Whipple Road Union City, California | 94587 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On June 10, 2010, Questcor Pharmaceuticals, Inc. (the Company) will be making presentations
to certain members of the investment community and, in connection therewith, will advance a
presentation (the Presentation) providing certain information about the Company. This
Presentation will be made available on the Companys website at www.Questcor.com as soon thereafter
as practicable. The Presentation is furnished under this Item 7.01 pursuant to Regulation FD and
is included as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto,
shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to liability under such section, nor
shall it be deemed incorporated by reference in any filing of the Company under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such
filing, unless expressly incorporated by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description |
|
99.1
|
Presentation made by Questcor Pharmaceuticals, Inc. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 10, 2010 | QUESTCOR PHARMACEUTICALS, INC. | |||
By: | /s/ Gary M. Sawka | |||
Gary M. Sawka Senior Vice President, Finance and Chief Financial Officer |
3
EXHIBIT INDEX
Exhibit No. | Description | |
99.1
|
Presentation made by Questcor Pharmaceuticals, Inc. |
4